Ketanserin tartrate | Serotonin 5-HT2A antagonist

Available Options

Size:PriceQuantity 
50 mg$55.00
200 mg$150.00
Request Quote / Bulk / Custom Size
Product Inquiry

Ketanserin tartrate (83846-83-7) is a selective serotonin 5-HT2A receptor antagonist (IC50 = 6.3 nM).1 Also exhibits significant selectivity for the human 5-HT1Dα receptor.2 Was shown to be effective for the treatment of hypertension following coronary artery surgery.3 Has been used to disrupt the hallucinogenic effects of psilocybin and to explore cognitive effects of the 5-HT2A receptor.4

References/Citations:

  1. Leysen et al. (1981), Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors; Life Sci. 28 1015
  2. Zgombick et al. (1995), Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes; Eur. J. Pharmacol. 291 9
  3. Vandenbroucke et al. (1994), Use of ketanserin in the treatment of hypertension following coronary artery surgery; J. Cardiothorac. Vasc. Anesth. 8 P324
  4. Quednow et al. (2012), Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers; Neuropsychopharmacology 37 630
5-HT2A antagonist, 83846-83-7, ketanserin, ketanserin supplier, ketanserin tartrate, Ketanserin tartrate supplier, R41468, selective 5-HT2A antagonist
Alternate Name:
R41468

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Ketanserin tartrate (83846-83-7) is a selective serotonin 5-HT2A receptor antagonist (IC50 = 6.3 nM).1 Also exhibits significant selectivity for the human 5-HT1Dα receptor.2 Was shown to be effective for the treatment of hypertension following coronary artery surgery.3 Has been used to disrupt the hallucinogenic effects of psilocybin and to explore cognitive effects of the 5-HT2A receptor.4

References/Citations:

  1. Leysen et al. (1981), Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors; Life Sci. 28 1015
  2. Zgombick et al. (1995), Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes; Eur. J. Pharmacol. 291 9
  3. Vandenbroucke et al. (1994), Use of ketanserin in the treatment of hypertension following coronary artery surgery; J. Cardiothorac. Vasc. Anesth. 8 P324
  4. Quednow et al. (2012), Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers; Neuropsychopharmacology 37 630